AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04628429
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: anti-CGRP-ligand monoclonal anti-body
Trial: NCT04628429
Drug: Fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-CGRP-ligand monoclonal anti-body
Trial: NCT00681889
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 Patients will receive treatment (Ranibizumab)
Trial: NCT00640848
Drug: almorexant
RxNorm normalized name: Almorexant
DrugBank: Almorexant (DB06673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 400 mg in two treatment sequences
Trial: NCT00640848
Drug: almorexant
RxNorm normalized name: Almorexant
DrugBank: Almorexant (DB06673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 200 mg in two treatment sequences
Trial: NCT00640848
Drug: almorexant
RxNorm normalized name: Almorexant
DrugBank: Almorexant (DB06673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 100 mg in two treatment sequences
Trial: NCT00640848
Drug: almorexant
RxNorm normalized name: Almorexant
DrugBank: Almorexant (DB06673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 50 mg mg in two treatment sequences
Trial: NCT00640848
Drug: almorexant
RxNorm normalized name: Almorexant
DrugBank: Almorexant (DB06673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 1000 mg in two treatment sequences
Trial: NCT02772744
Drug: Daclatasvir 60 MG Oral Tablet [Daklinza]
RxNorm normalized name: Daclatasvir 60 MG Oral Tablet [DAKLINZA]
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
Trial: NCT02772744
Drug: Sofosbuvir 400 MG Oral Tablet [Sovaldi]
RxNorm normalized name: Sofosbuvir 400 MG Oral Tablet [SOVALDI]
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
Trial: NCT02772744
Drug: Ribavirin Oral Product
RxNorm normalized name: ribavirin Oral Product
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (twice-daily) dosed according to body weight (\<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
Trial: NCT00655629
Drug: Vardenafil ODT (STAXYN, BAY38-9456)
RxNorm normalized name: Vardenafil Orally Disintegrating Tablets
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
Trial: NCT00654082
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
Trial: NCT03529890
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1
Trial: NCT02511886
Drug: Arbaclofen Placarbil
RxNorm normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaclofen Placarbil
Trial: NCT01362608
Drug: Canakinumab, ACZ885
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab and placebo matching to triamcinolone acetonide
Trial: NCT01362608
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 40 mg and placebo matching to canakinumab
Trial: NCT03403439
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference and Test Treatment
Trial: NCT03403439
Drug: itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test treatment
Trial: NCT01766245
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
Trial: NCT02366247
Drug: PEG-Tα1
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.2mg/ml, once a week, taken subcutaneously
Trial: NCT02366247
Drug: Placebo to match PEG-Tα1
RxNorm normalized name: HLA-matched Virus Specific T Cells
DrugBank: Virus Specific T-Cell (DB15735)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml, once a week, taken subcutaneously
Trial: NCT01301313
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
Trial: NCT00003727
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003727
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003727
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003727
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02255461
Drug: palbociclib isethionate
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02366247
Drug: Adefovir
RxNorm normalized name: Adefovir
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, once daily, taken orally for 48 weeks
Trial: NCT00881140
Drug: mifepristone vaginal tablets
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily use of 10 mg administrated per vagina for 3 months
Trial: NCT01776606
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
Trial: NCT04252261
Drug: sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
Trial: NCT01048658
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
Trial: NCT02456454
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Liquid risperidone
Trial: NCT02456454
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid valproic acid
Trial: NCT01465451
Drug: intra-operative 5-FU chemotherapy
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A.
Trial: NCT02527785
Drug: Oxaliplatin, Irinotecan, S-1(OIS)
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7
Trial: NCT03235947
Drug: Fosfomycin disodium
RxNorm normalized name: fosfomycin disodium
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
Trial: NCT03235947
Drug: Trimethoprim / Sulfamethoxazole
RxNorm normalized name: Septra 40/200 (trimethoprim / sulfamethoxazole) per 5 ML Oral Suspension
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
Trial: NCT01091142
Drug: NP001
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
Trial: NCT01878227
Drug: Coenzyme A
RxNorm normalized name: Coenzyme A
DrugBank: Coenzyme A (DB01992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme A 400mg per day
Trial: NCT01878227
Drug: Fenofibrate 200mg
RxNorm normalized name: FENOFIBRATE 200MG CAP
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200mg per day
Trial: NCT01688999
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
Trial: NCT01159249
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00127179
Drug: MK0906, finasteride / Duration of Treatment: 48 weeks
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00220350
Drug: leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03012230
Drug: Ruxolitinib Phosphate
RxNorm normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00454480
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00454480
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00454480
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00454480
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00454480
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00454480
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00454480
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00454480
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00546871
Drug: Immune Globulin Intravenous (Human), 10%
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
Trial: NCT00454480
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00454480
Drug: tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01449006
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
Trial: NCT02685033
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03460210
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription atomoxetine medication
Trial: NCT00028301
Drug: Atazanavir
RxNorm normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01197781
Drug: FOSTAMATIN
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablets - single dose
Trial: NCT00028301
Drug: Lopinavir/Ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01197781
Drug: Verapamil
RxNorm normalized name: Verapamil
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets - administered 3 times daily over 4 days
Trial: NCT00005890
Drug: corticotropin
RxNorm normalized name: Corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03328117
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Over-encapsulated 100 mg imatinib mesilate tablets
Trial: NCT02124213
Drug: PF-06412562
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
Trial: NCT02124213
Drug: PF-06412562
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional.
Trial: NCT00242541
Drug: Octreotide acetate
RxNorm normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00964184
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01303835
Drug: LDN
RxNorm normalized name: LDN-193189
DrugBank: LDN-193189 (DB18051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
Trial: NCT01136408
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 110 mg capsule, twice a day, oral administration
Trial: NCT01136408
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate 150 mg capsule, twice a day, oral administration
Trial: NCT01136408
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-adjusted warfarin based on target INR values
Trial: NCT00270062
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00566462
Drug: perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg/d for 14 days followed by 4 mg/d for 14 days
Trial: NCT00592904
Drug: E2007
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
Trial: NCT00056836
Drug: rhuFab V2 (ranibizumab)
RxNorm normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03383068
Drug: Acarbose 100 MG
RxNorm normalized name: acarbose 100 MG
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for metformin uneffective subjects, using acarbose for 3 months
Trial: NCT03383068
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for metformin uneffective subjects, using Exenatide for 3 months
Trial: NCT03383068
Drug: Orlistat
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for metformin uneffective subjects, using Orlistatfor 3 months
Trial: NCT03383068
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin effective subjects,act as control group
Trial: NCT01619813
Drug: Docetaxel, Reolysin and Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
Trial: NCT00832416
Drug: Tramadol Once A Day
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One Tramadol Once A Day tablet at randomized dose daily.
Trial: NCT01619813
Drug: Docetaxel and Prednisone
RxNorm normalized name: Docetaxel
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
Trial: NCT00058188
Drug: calcium gluconate
RxNorm normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04308954
Drug: [18F]flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
Trial: NCT03466671
Drug: TTA-121
RxNorm normalized name: Tartaric Acid
DrugBank: L-tartaric acid (DB09459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A nove intranasal spray of oxytocin and placebo
Trial: NCT04523467
Drug: Ginsenoside Rg3
RxNorm normalized name: Ginsenoside Rg3
DrugBank: Ginsenoside Rg3 (DB19257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An active ingredient extracted from ginseng leachate, which can restrain angiogenesis and reduce the expression of programmed cell death ligand 1 (PD-L1) on the tumor cell surface and block the binding of programmed cell death 1 (PD-1) and PD-L1
Trial: NCT00227812
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02017457
Drug: Azacytidine
RxNorm normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped.
Trial: NCT00141401
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00028795
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01985750
Drug: d-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
Trial: NCT00087334
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00087334
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00428883
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05060198
Drug: Dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DP is the current second-line antimalarial in Kenya, per Kenya Ministry of Health.
Trial: NCT03934203
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03934203
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet